AbCellera Biologics (NASDAQ: ABCL) shares surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst expectations.
The biotechnology company reported a quarterly loss of $0.12 per share, beating the analyst consensus estimate of a $0.15 loss by 21.05%. This represents an improvement from the $0.13 per share loss reported in the same period last year. More impressively, AbCellera's quarterly sales skyrocketed to $17.084 million, surpassing the analyst consensus estimate of $5.824 million by a staggering 193.31%. This marks a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year.
AbCellera Biologics, known for its AI-powered antibody discovery platform, has been gaining attention in the biotech sector. The company's strong performance this quarter, particularly its ability to more than double its sales year-over-year, suggests growing demand for its innovative technologies. As investors digest this positive earnings surprise, it could potentially lead to revised outlook and increased interest in ABCL stock moving forward.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.